利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1125 条记录 (耗时 0.04 秒)

    Drug delivery device
    2.
    外观设计
    Drug delivery device 有权

    公开(公告)号：USD1029237S1

    公开(公告)日：2024-05-28

    申请号：US29792973

    申请日：2022-05-03

    申请人： Sandoz AG

    设计人： Leon Rizner

    摘要： FIG. 1 is a top perspective view of a first embodiment of a drug delivery device in accordance with my new design;
    FIG. 2 is a front elevational view thereof;
    FIG. 3 is a rear elevational view thereof;
    FIG. 4 is a right side elevational view thereof;
    FIG. 5 is a left side elevational view thereof;
    FIG. 6 is a top view thereof;
    FIG. 7 is a top perspective view of a second embodiment of the drug delivery device;
    FIG. 8 is a front elevational view thereof;
    FIG. 9 is a rear elevational view thereof;
    FIG. 10 is a right side elevational view thereof;
    FIG. 11 is a left side elevational view thereof; and,
    FIG. 12 is a top view thereof.

    MULTI-COMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR
    3.
    发明申请
    MULTI-COMPONENT CRYSTALS OF AN ORALLY AVAILABLE HIF PROLYL HYDROXYLASE INHIBITOR 有权

    公开(公告)号：US20220024874A1

    公开(公告)日：2022-01-27

    申请号：US17297790

    申请日：2019-11-07

    申请人： Sandoz AG

    发明人： Verena Adamer ,  Andrea Thaler ,  Erwin Schreiner

    IPC分类号： C07D213/81 ,  C07D207/16

    摘要： The present invention relates to crystalline compounds comprising vadadustat and L-proline and processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one or more of the crystalline compounds of the present invention and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia for example in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).

    Constitutive yeast LLP promotor-based expression systems
    4.
    发明授权
    Constitutive yeast LLP promotor-based expression systems 有权

    公开(公告)号：US11203620B2

    公开(公告)日：2021-12-21

    申请号：US15554552

    申请日：2016-03-02

    申请人： Sandoz AG

    发明人： Clemens Achmüller ,  Ferdinand Zepeck ,  Franz Hartner ,  Thomas Specht

    IPC分类号： C07K14/39 ,  C12N15/81 ,  C07K14/395

    摘要： The present invention provides a modified eukaryotic cell wherein the modified eukaryotic cell is not able to provide an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like gene.

    Crystalline Eravacycline Bis-Hydrochloride
    6.
    发明申请
    Crystalline Eravacycline Bis-Hydrochloride 有权

    公开(公告)号：US20210253521A1

    公开(公告)日：2021-08-19

    申请号：US17226367

    申请日：2021-04-09

    申请人： Sandoz AG

    发明人： Hannes Lengauer

    IPC分类号： C07D207/06 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00

    摘要： The invention relates to crystalline eravacycline Ns-hydrochloride and to a process for its preparation. Furthermore, the invention relates to the use of crystalline eravacycline bis-hydrochloride for the preparation of pharmaceutical compositions. The invention further relates to pharmaceutical compositions comprising an effective amount of crystalline eravacycline bis-hydrochloride. The pharmaceutical compositions of the present invention can be used as medicaments, in particular for treatment and/or prevention of bacterial infections e.g. caused by Gram negative pathogens or Gram positive pathogens, in particular caused by multidrug resistant Gram negative pathogens. The pharmaceutical compositions of the present invention can thus be used as medicaments for e.g. the treatment of complicated intra-abdominal and urinary tract infection

    Crystalline forms of valbenazine salts
    10.
    发明授权
    Crystalline forms of valbenazine salts 有权

    公开(公告)号：US10954235B2

    公开(公告)日：2021-03-23

    申请号：US16488735

    申请日：2018-02-01

    申请人： Sandoz AG

    发明人： Christoph Langes ,  Ulrich Griesser ,  Erwin Schreiner ,  Marijan Stefinovic

    IPC分类号： C07D471/06 ,  A61K31/4745 ,  C07D471/04

    摘要： The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia.